HALO logo
halo search icon
Coherus Oncology, Inc.
Coherus Oncology, Inc.
CHRS · NAS

Coherus Oncology, Inc.

US$1.51

Price Arrow0.03 (2.03%)
20/05/2026 04:00:01 PM
All-CompaniesAll-ConsensusEngulfing BullishEngulfing Bullish (Realtime)HALO AllHALO Consensus ValueHALO Momentum
Consensus Score
Lock Icon/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

Coherus Oncology, Inc. Overview

CHRS Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

HALO Model

Mqv

Very Weak

Garp

Very Weak

Mqv Small

Neutral

Valuation

Value

Lock Icon

Consensus

Lock Icon

Momentum

Price

Weak

Earnings

Neutral

Growth

Earnings

Neutral

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About CHRS

icon

Telephone

1.650.649.3530

icon

Address

Suite 600, 333 Twin Dolphin Drive, Redwood City, CA 94065

Description

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

CHRS Price Chart

Key Stats

Market Cap

US$228.29M

PE

18.20

EV/EBITDA

N/A

Dividends Overview

DIV Yield

0%

Franking

0%

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.71 - 2.62

Trade Value (12mth)

US$558,854.00

1 week

-5.73%

1 month

-18.68%

YTD

8.03%

1 year

91.49%

All time high

38.10

Key Fundamentals

EPS 3 yr Growth

-61.30%

EBITDA Margin

-416.40%

Operating Cashflow

-$139m

Free Cash Flow Return

-99.90%

ROIC

-132.00%

Interest Coverage

-19.50

Quick Ratio

1.40

Other Data

Shares Outstanding (Fully Diluted)

136m

HALO Sector

Healthcare

Next Company Report Date

15-Mar-27

Next Ex Dividend Date

N/A

Next Dividend Pay Date

N/A

Reporting Currency

USD

Short Sell (% of issue)

0.00

CHRS Announcements

Latest Announcements

DateAnnouncements
12 May 26
12 May 26
12 May 26
12 May 26
29 April 26

CHRS Fundamentals

Per Share Records

Historical data

Forecast data

USD2021202220232024202320242025202620272028
Per Share, Growth & Valuations
EPS (Basic)
$locklocklocklock-2.53-1.29-1.45locklocklock
EPS (Fully Diluted)
$locklocklocklock-2.53-1.29-1.45locklocklock
Growth
%locklocklocklock32.848.8-12.5locklocklock
PE
XlocklocklocklockN/A5.618.2locklocklock
EV/EBITDA
XlocklocklocklockN/AN/AN/Alocklocklock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

0%

Franking Level

0%

DPSg

N/A

Quality Yield

lock

Falling Divs over next 2

lock

Want to learn more?Frequently asked questions.
What is the current share price of Coherus Oncology, Inc. (CHRS:NAS)?
Halo FAQ
The current share price of Coherus Oncology, Inc. (CHRS:NAS) is USD$1.51.
What is the 52-week high share price for Coherus Oncology, Inc. (CHRS:NAS)?
Halo FAQ
The 52-week high share price for Coherus Oncology, Inc. (CHRS:NAS) is USD$2.62.
What is the 52-week low share price for Coherus Oncology, Inc. (CHRS:NAS)?
Halo FAQ
The 52-week low share price for Coherus Oncology, Inc. (CHRS:NAS) is USD$0.71.
What is the dividend yield for Coherus Oncology, Inc. (CHRS:NAS)?
Halo FAQ
Coherus Oncology, Inc. (CHRS:NAS) does not pay a dividend.
What was Coherus Oncology, Inc. (CHRS:NAS) last dividend payment?
Halo FAQ
Coherus Oncology, Inc. (CHRS:NAS) does not pay a dividend.
What is the franking level for Coherus Oncology, Inc. (CHRS:NAS)?
Halo FAQ
Coherus Oncology, Inc. (CHRS:NAS) has a franking level of 0.00%.
In which sector is Coherus Oncology, Inc. (CHRS:NAS) classified?
Halo FAQ
Coherus Oncology, Inc. (CHRS:NAS) is classified in the Healthcare.
What is the price-to-earnings (P/E) ratio for Coherus Oncology, Inc. (CHRS:NAS)?
Halo FAQ
The current P/E ratio for Coherus Oncology, Inc. (CHRS:NAS) is 18.20.

See beyond the curve.

One solution for research, investing and portfolio management.